Literature DB >> 25042571

A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment.

Stuart J Ellem1, Renea A Taylor, Luc Furic, Ola Larsson, Mark Frydenberg, David Pook, John Pedersen, Bree Cawsey, Andrew Trotta, Eleanor Need, Grant Buchanan, Gail P Risbridger.   

Abstract

Prostate cancer is hormone-dependent and regulated by androgens as well as oestrogens. The tumour microenvironment also provides regulatory control, but the balance and interplay between androgens and oestrogens at the human prostate tumour interface is unknown. This study reveals a central and dominant role for oestrogen in the microenvironment, fuelling a pro-tumourigenic loop of inflammatory cytokines involving recruitment of mast cells by carcinoma-associated fibroblasts (CAFs). Mast cell numbers were increased in human PCa clinical specimens, specifically within the peritumoural stroma. Human mast cells were also shown to express ERα and ERβ, with oestradiol directly stimulating mast cell proliferation and migration as well as altered cytokine/chemokine expression. There was a significant shift in the oestrogen:androgen balance in CAFs versus normal prostatic fibroblasts (NPFs), with a profound increase to ER:AR expression. Androgen signalling is also reduced in CAFs, while ERα and ERβ transcriptional activity is not, allowing oestrogen to dictate hormone action in the tumour microenvironment. Gene microarray analyses identified CXCL12 as a major oestrogen-driven target gene in CAFs, and CAFs recruit mast cells via CXCL12 in a CXCR4-dependent manner. Collectively, these data reveal multicellular oestrogen action in the tumour microenvironment and show dominant oestrogen, rather than androgen, signalling at the prostatic tumour interface.
Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  CXCL12; mast cells; microenvironment; oestrogen; prostate; stroma

Mesh:

Substances:

Year:  2014        PMID: 25042571     DOI: 10.1002/path.4386

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

1.  Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B.

Authors:  Hui-Fang Zhu; Xu-Hui Zhang; Chuan-Sha Gu; Yan Zhong; Ting Long; Yi-Dan Ma; Zhi-Yan Hu; Zu-Guo Li; Xiao-Yan Wang
Journal:  Cancer Biol Ther       Date:  2019-03-20       Impact factor: 4.742

Review 2.  Inflammation and prostate cancer: friends or foe?

Authors:  Gianluigi Taverna; Elisa Pedretti; Giuseppe Di Caro; Elena Monica Borroni; Federica Marchesi; Fabio Grizzi
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

Review 3.  Molecular mechanism underlying the tumor-promoting functions of carcinoma-associated fibroblasts.

Authors:  Yali Han; Yanwen Zhang; Tanghong Jia; Yuping Sun
Journal:  Tumour Biol       Date:  2015-02-15

4.  A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Authors:  Oren Levy; W Nathaniel Brennen; Edward Han; David Marc Rosen; Juliet Musabeyezu; Helia Safaee; Sudhir Ranganath; Jessica Ngai; Martina Heinelt; Yuka Milton; Hao Wang; Sachin H Bhagchandani; Nitin Joshi; Neil Bhowmick; Samuel R Denmeade; John T Isaacs; Jeffrey M Karp
Journal:  Biomaterials       Date:  2016-03-17       Impact factor: 12.479

Review 5.  Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.

Authors:  Alessandro Sciarra; Alessandro Gentilucci; Stefano Salciccia; Federico Pierella; Flavio Del Bianco; Vincenzo Gentile; Ida Silvestri; Susanna Cattarino
Journal:  J Inflamm (Lond)       Date:  2016-11-25       Impact factor: 4.981

6.  Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model.

Authors:  Stefano Garetto; Claudia Sardi; Elisa Martini; Giuliana Roselli; Diego Morone; Roberta Angioni; Beatrice Claudia Cianciotti; Anna Elisa Trovato; Davide Giuseppe Franchina; Giovanni Francesco Castino; Debora Vignali; Marco Erreni; Federica Marchesi; Cristiano Rumio; Marinos Kallikourdis
Journal:  Oncotarget       Date:  2016-07-12

7.  Estrogen-induced SDF-1α production promotes the progression of ER-negative breast cancer via the accumulation of MDSCs in the tumor microenvironment.

Authors:  Liquan Ouyang; Weilong Chang; Bin Fang; Jieting Qin; Xincai Qu; Fanjun Cheng
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

8.  Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts.

Authors:  Jennifer C Y Lo; Ashlee K Clark; Natasha Ascui; Mark Frydenberg; Gail P Risbridger; Renea A Taylor; Matthew J Watt
Journal:  Oncotarget       Date:  2016-07-26

9.  Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.

Authors:  Adam W Nelson; Arnoud J Groen; Jodi L Miller; Anne Y Warren; Kelly A Holmes; Gerard A Tarulli; Wayne D Tilley; Benita S Katzenellenbogen; John R Hawse; Vincent J Gnanapragasam; Jason S Carroll
Journal:  Mol Cell Endocrinol       Date:  2016-11-23       Impact factor: 4.102

10.  Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.

Authors:  Thomas Kryza; Lakmali M Silva; Nathalie Bock; Ruth A Fuhrman-Luck; Carson R Stephens; Jin Gao; Hema Samaratunga; Mitchell G Lawrence; John D Hooper; Ying Dong; Gail P Risbridger; Judith A Clements
Journal:  Mol Oncol       Date:  2017-08-10       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.